Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review

X Zou, XY Tang, ZY Qu, ZW Sun, CF Ji, YJ Li… - International Journal of …, 2022 - Elsevier
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …

Therapeutic targets and emerging treatments in advanced chondrosarcoma

S Miwa, N Yamamoto, K Hayashi, A Takeuchi… - International Journal of …, 2022 - mdpi.com
Simple Summary Chondrosarcomas develop chemoresistance to standard anticancer
drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve …

Targeting OCT3 attenuates doxorubicin-induced cardiac injury

KM Huang, M Zavorka Thomas… - Proceedings of the …, 2021 - National Acad Sciences
Doxorubicin is a commonly used anticancer agent that can cause debilitating and
irreversible cardiac injury. The initiating mechanisms contributing to this side effect remain …

Avapritinib: a selective inhibitor of KIT and PDGFRα that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines

CP Wu, S Lusvarghi, JC Wang, SH Hsiao… - Molecular …, 2019 - ACS Publications
The frequent occurrence of multidrug resistance (MDR) conferred by the overexpression of
ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 in cancer cells remains a …

Multi-target ABC transporter modulators: what next and where to go?

SM Stefan - Future Medicinal Chemistry, 2019 - Taylor & Francis
Several ABC transporters (eg, ABCB1, ABCB4, ABCC1–5, ABCC10, ABCG2 and ABCG4)
are known to contribute to the phenomenon of cancer-related multidrug resistance (MDR)[1] …

Sitravatinib sensitizes ABCB1-and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

CP Wu, SH Hsiao, YH Huang, LC Hung, YJ Yu… - Cancers, 2020 - mdpi.com
The development of multidrug resistance (MDR) in cancer patients driven by the
overexpression of ATP-binding cassette (ABC) transporter ABCB1 or ABCG2 in cancer cells …

The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

CP Wu, TH Hung, S Lusvarghi, YH Chu… - Biochemical …, 2021 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) drug transporter ABCB1 (P-
glycoprotein, P-gp) or ABCG2 (breast cancer resistance protein, BCRP) in cancer cells often …

Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs

CP Wu, TH Hung, SH Hsiao, YH Huang, LC Hung… - Cancers, 2020 - mdpi.com
The development of multidrug resistance (MDR) in cancer patients, which is often
associated with the overexpression of ABCB1 (MDR1, P-glycoprotein) in cancer cells …

The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study

L Porcelli, M Garofoli, R Di Fonte, L Fucci… - Scientific Reports, 2020 - nature.com
Standard chemotherapy for soft tissue sarcomas has shown limited efficacy. Here, we
sought to evaluate whether β-adrenergic receptor (β-AR) signalling contributed to the …

Furmonertinib, a third-generation EGFR tyrosine kinase inhibitor, overcomes multidrug resistance through inhibiting ABCB1 and ABCG2 in cancer cells

CP Wu, YC Li, M Murakami, SH Hsiao, YC Lee… - International Journal of …, 2023 - mdpi.com
ATP-binding cassette transporters, including ABCB1 (P-glycoprotein) and ABCG2
(BCRP/MXR/ABCP), are pivotal in multidrug resistance (MDR) development in cancer …